Global Brugada Syndrome Market Size study & Forecast, by Diagnosis (Electrocardiogram, Electrophysiology Test, Genetic Testing, and Others), Treatment (Implantable Cardioverter-Defibrillator, and Drug Therapy), and End User (Hospitals & Clinics, Surgical

Global Brugada Syndrome Market Size study & Forecast, by Diagnosis (Electrocardiogram, Electrophysiology Test, Genetic Testing, and Others), Treatment (Implantable Cardioverter-Defibrillator, and Drug Therapy), and End User (Hospitals & Clinics, Surgical Centers, Diagnostic Centers, and Others) and Regional Analysis, 2022-2029

Global Brugada Syndrome Market is valued at approximately USD 1.32 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. Brugada Syndrome is a rare genetic disorder that affects the way electrical signals pass through the heart. It is an autosomal dominant genetic disorder and can be inherited from just one parent. Brugada Syndrome causes disruptions to the normal rhythm of the heart. Signs and symptoms associated with Brugada Syndrome include dizziness. fainting. gasping and laboured breathing, irregular heartbeats, or palpitations as well as extremely fast and chaotic heartbeat among others. The increasing incidence of heart-related diseases and growing prevalence of Brugada Syndrome as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Health Organization (WHO)’s estimates – as of 2019, globally around 17.9 million people lost their lives due to CVDs, witnessing for over 32% of all global deaths. In addition, around 85% CVD related deaths are caused by heart attack stroke. Moreover, as per The National Organization for Rare Disorders – in 2019, the prevalence of Brugada Syndrome in the United States was estimated at 5 in 10,000 people. Also, rising awareness of genetic syndromes and growing pharmaceuticals & biotechnology industry would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Brugada Syndrome stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Brugada Syndrome Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the presence of key market players as well as availability of well-established healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as the rising prevalence of Brugada Syndrome as well as growing healthcare infrastructure in the region.

Major market player included in this report are:
Novartis AG
F. Hoffmann-La Roche Ltd
Boehringer Ingelheim International GmbH.
Pfizer Inc.
Ionis Pharmaceuticals Inc.
Abbott
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited.
AstraZeneca
Cytokinetics, Inc.

Recent Developments in the Market:
In October 2020, USA-based Abbott Laboratories launched new Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronisation Therapy Defibrillator (CRT-D) devices. These new devices are intended for the patient suffering from abnormal heart rhythms and heart failure.

In December 2021, Massachusetts, USA-based Boston Scientific announced a clinical trial of its first modular cardiac rhythm implant system. This new system is comprised of a leadless pacemaker and an implantable cardioverter defibrillator. This new system aimed at controlling the abnormal beating of the heart.

Global Brugada Syndrome Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered

Diagnosis, Treatment, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Diagnosis
Electrocardiogram
Electrophysiology Test
Genetic Testing
Others
By Treatment
Implantable Cardioverter-Defibrillator
Drug Therapy
By End User
Hospitals & Clinics
Surgical Centers
Diagnostic Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned

Novartis AG
F. Hoffmann-La Roche Ltd
Boehringer Ingelheim International GmbH.
Pfizer Inc.
Ionis Pharmaceuticals Inc.
Abbott
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited.
AstraZeneca
Cytokinetics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.